Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30270577 | 1.00 | PARP1 (0.71) | PARP1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL531752 | 0.89 | ALDH1A1 (0.67) | PARP1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL24124197 | 0.84 | ALDH1A1 (0.64) | PARP1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL24124992 | 0.84 | ALDH1A1 (0.54) | PARP1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL531858 | 0.83 | PARP1 (1.00) | PARP1MAPTKMT2ATSHRCYP1A2 | |
| SCHEMBL24124997 | 0.82 | ALDH1A1 (0.59) | PARP1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL8192718 | 0.82 | ALDH1A1 (0.77) | ALDH1A1MAPTPOLBKMT2ATSHR | |
| SCHEMBL24124625 | 0.82 | ALDH1A1 (0.56) | PARP1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL531798 | 0.82 | TSHR (0.74) | PARP1ALDH1A1MAPTTSHRGAA | |
| SCHEMBL24125259 | 0.81 | RAB9A (0.46) | PARP1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | PARP1 1599/4885ALDH1A1 2654/4885MAPT 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.